\u27While we can, we will\u27: exploring food choice and dietary behaviour amongst independent older Australians

Aim Burgeoning proportions of populations aged over 65 years impose an increased financial burden upon governments for the provision of associated health and aged-care services. Strategies are therefore required to mitigate service demand through the preservation of good health and independence into old age. Nutrition has been acknowledged as a key factor for realisation of this goal. The objective of the present study was to investigate factors responsible for shaping food shopping, cooking and eating behaviours amongst healthy, independently living Australians aged 60 years and over. Methods Eighteen (5 male, 13 female) independently living residents sourced from three low-care Illawarra Retirement Trust (IRT) lifestyle residential facilities volunteered to take part in the present study. All participants were aged 60 years or more and in relatively good health. Semi-structured focus groups were implemented to explore factors influencing the selection, acquisition and preparation of food. Each session was digitally recorded, transcribed verbatim and subsequently examined using content and thematic analysis. Results Ten sub-themes were identified and grouped into three broader themes: adaptation, psychosocial parameters and food landscape. Findings reflect an active self-determination to retain independence, with a focus on the maintenance of favourable nutritional status. A sense of resourcefulness was evident through the development of strategies to overcome potential barriers to healthy eating. Conclusions Factors that influence the food choices of community-living older Australians are complex and multifactorial, and underpinned by a strong desire for independence and control over personal health outcomes. Studies involving larger, more demographically diverse participant groups are required to elicit socially acceptable strategies that will empower older Australians to sustain their health and independence for the longer term

Usability of Food and Beverage Packs in Hospital - Experiences from the Renal Ward

Abstract presented at The 21st IAPRI World Conference on Packaging, 19-22 June 2018, Zhuhai, Chin

Audit of the national meal guidelines for home‐delivered and centre‐based meal programs

Objective To evaluate the impact of the National Meal Guidelines on service providers and caterers involved in home‐delivered and centre‐based meal programs in Australia. Methods An anonymous online survey was conducted to explore the uptake of the guidelines by participants and evaluate the impact on their practice. Closed questions were analysed using χ2 and Fisher\u27s exact tests, while open‐ended questions underwent thematic analysis to identify key themes. Results A total of 101 out of 441 participants completed the survey (response rate of 23.0%). Most participants (69%) were currently referring to the guidelines, particularly for nutrition guidelines, menu planning and auditing tools. Key barriers to implementation were cost, supplier compliance issues and lack of staff education. Conclusions The National Meal Guidelines have been successfully implemented in many services around Australia. Further research should investigate their impact on customer satisfaction and external supplier compliance

Lean body mass associated with upper body strength in healthy older adults while higher body fat limits lower extremity performance and endurance

Impaired strength adversely influences an older person\u27s ability to perform activities of daily living. A cross-sectional study of 117 independently living men and women (age = 73.4 9.4 year; body mass index (BMI) = 27.6 4.8 kg/m2) aimed to assess the association between body composition and: (1) upper body strength (handgrip strength, HGS); (2) lower extremity performance (timed up and go (TUG) and sit to stand test (STS)); and (3) endurance (6-minute walk (SMWT). Body composition (% fat; lean body mass (LBM)) was assessed using bioelectrical impedance. Habitual physical activity was measured using the Minnesota Leisure Time Physical Activity Questionnaire (MLTPA) and dietary macronutrient intake, assessed using 24 h recalls and 3-day food records. Regression analyses included the covariates, protein intake (g/kg), MLTPA, age and sex. For natural logarithm (Ln) of right HGS, LBM (p \u3c 0.001) and % body fat (p \u3c 0.005) were significant (r2 = 46.5%; p \u3c 0.000). For left LnHGS, LBM (p \u3c 0.000), age (p = 0.036), protein intake (p = 0.015) and LnMLTPA (p = 0.015) were significant (r2 = 0.535; p \u3c 0.000). For SMW, % body fat, age and LnMLTPA were significant (r2 = 0.346; p \u3c 0.000). For STS, % body fat and age were significant (r2 = 0.251; p \u3c 0.000). LBM is a strong predictor of upper body strength while higher % body fat and lower physical activity are associated with poorer outcomes on tests of lower extremity performance

Arbaclofen in fragile X syndrome: results of phase 3 trials

Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for social avoidance in FXS. Methods: Two phase 3 placebo-controlled trials were conducted, a flexible dose trial in subjects age 12-50 (209FX301, adolescent/adult study) and a fixed dose trial in subjects age 5-11 (209FX302, child study). The primary endpoint for both trials was the Social Avoidance subscale of the Aberrant Behavior Checklist-Community Edition, FXS-specific (ABC-C FX ). Secondary outcomes included other ABC-C FX subscale scores, Clinical Global Impression-Improvement (CGI-I), Clinical Global Impression-Severity (CGI-S), and Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Socialization domain score. Results: A total 119 of 125 randomized subjects completed the adolescent/adult study (n = 57 arbaclofen, 62 placebo) and 159/172 completed the child study (arbaclofen 5 BID n = 38; 10 BID n = 39; 10 TID n = 38; placebo n = 44). There were no serious adverse events (AEs); the most common AEs included somatic (headache, vomiting, nausea), neurobehavioral (irritability/agitation, anxiety, hyperactivity), decreased appetite, and infectious conditions, many of which were also common on placebo. In the combined studies, there were 13 discontinuations (n = 12 arbaclofen, 1 placebo) due to AEs (all neurobehavioral). The adolescent/adult study did not show benefit for arbaclofen over placebo for any measure. In the child study, the highest dose group showed benefit over placebo on the ABC-C FX Irritability subscale (p = 0.03) and Parenting Stress Index (PSI, p = 0.03) and trends toward benefit on the ABC-C FX Social Avoidance and Hyperactivity subscales (both p < 0.1) and CGI-I (p = 0.119). Effect size in the highest dose group was similar to effect sizes for FDA-approved serotonin reuptake inhibitors (SSRIs). Conclusions: Arbaclofen did not meet the primary outcome of improved social avoidance in FXS in either study. Data from secondary measures in the child study suggests younger patients may derive benefit, but additional studies with a larger cohort on higher doses would be required to confirm this finding. The reported studies illustrate the challenges but represent a significant step forward in translating targeted treatments from preclinical models to clinical trials in humans with FXS

Uteroplacental insufficiency temporally exacerbates salt-induced hypertension associated with a reduced natriuretic response in male rat offspring

Intrauterine growth restriction increases the risk of developing chronic diseases in adulthood. Lifestyle factors, such as poor dietary choices, may elevate this risk. We determined whether being born small increases the sensitivity to a dietary salt challenge, in the context of hypertension, kidney disease and arterial stiffness. Bilateral uterine vessel ligation or sham surgery (offspring termed Restricted and Control, respectively) was performed on 18-day pregnant WKY rats. Male offspring were allocated to receive a diet high in salt (8% sodium chloride) or remain on standard rat chow (0.52% sodium chloride) from 20-26\ua0weeks of age for 6\ua0weeks. Systolic blood pressure (tail-cuff), renal function (24\ua0h urine excretions) and vascular stiffness (pressure myography) were assessed. Restricted males were born 15% lighter than Controls and remained smaller throughout the study. Salt-induced hypertension was exacerbated in Restricted offspring, reaching a peak systolic pressure of ∼175\ua0mmHg earlier than normal weight counterparts. The natriuretic response to high dietary salt in Restricted animals was less than in Controls and may explain the early rise in arterial pressure. Growth restricted males allocated to high salt diet also had increased passive arterial stiffness of mesenteric resistance arteries. Other aspects of renal function, including salt-induced hyperfiltration, albuminuria and glomerular damage were not exacerbated by uteroplacental insufficiency. This study demonstrates that male offspring exposed to uteroplacental insufficiency and born small have an increased sensitivity to salt-induced hypertension and arterial remodelling. This article is protected by copyright. All rights reserved

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.Seaside Therapeutics Inc

ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries.

This review summarizes the last decade of work by the ENIGMA (Enhancing NeuroImaging Genetics through Meta Analysis) Consortium, a global alliance of over 1400 scientists across 43 countries, studying the human brain in health and disease. Building on large-scale genetic studies that discovered the first robustly replicated genetic loci associated with brain metrics, ENIGMA has diversified into over 50 working groups (WGs), pooling worldwide data and expertise to answer fundamental questions in neuroscience, psychiatry, neurology, and genetics. Most ENIGMA WGs focus on specific psychiatric and neurological conditions, other WGs study normal variation due to sex and gender differences, or development and aging; still other WGs develop methodological pipelines and tools to facilitate harmonized analyses of "big data" (i.e., genetic and epigenetic data, multimodal MRI, and electroencephalography data). These international efforts have yielded the largest neuroimaging studies to date in schizophrenia, bipolar disorder, major depressive disorder, post-traumatic stress disorder, substance use disorders, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, autism spectrum disorders, epilepsy, and 22q11.2 deletion syndrome. More recent ENIGMA WGs have formed to study anxiety disorders, suicidal thoughts and behavior, sleep and insomnia, eating disorders, irritability, brain injury, antisocial personality and conduct disorder, and dissociative identity disorder. Here, we summarize the first decade of ENIGMA's activities and ongoing projects, and describe the successes and challenges encountered along the way. We highlight the advantages of collaborative large-scale coordinated data analyses for testing reproducibility and robustness of findings, offering the opportunity to identify brain systems involved in clinical syndromes across diverse samples and associated genetic, environmental, demographic, cognitive, and psychosocial factors

A Hubble Space Telescope Survey for Resolved Companions of Planetary-Nebula Nuclei

We report results of an HST "snapshot" survey aimed at finding resolved binary companions of the central stars of Galactic planetary nebulae (PNe). Using WF/PC and WFPC2, we searched the fields of 113 PNe for stars whose close proximity to the central star suggests a physical association. We find 10 binary nuclei that are very likely to be physically associated, and another six that are possible binary associations. By correcting for interstellar extinction and placing the central stars' companions on the main sequence, we derive distances to the objects, and thereby significantly increase the number of PNe with reliable distances. Comparison of our derived distances with those obtained from various statistical methods shows that all of the latter have systematically overestimated the distances, by factors ranging up to a factor of two or more. We show that this error is most likely due to the fact that the properties of our PNe with binary nuclei are systematically different from those of PNe used heretofore to calibrate statistical methods. Specifically, our PNe tend to have lower surface brightnesses at the same physical radius than the traditional calibration objects. This difference may arise from a selection effect: the PNe in our survey are typically nearby, old nebulae, whereas most of the objects that calibrate statistical techniques are low-latitude, high-surface-brightness, and more distant nebulae. As a result, the statistical methods that seem to work well with samples of distant PNe, e.g., those in the Galactic bulge or external galaxies, may not be applicable to the more diverse population of local PNe.Comment: 37 text pages, 17 table pages, 9 figures. Accepted by Astronomical Journal for June 1999 issu

Bone Marrow Osteoblast Damage by Chemotherapeutic Agents

Hematopoietic reconstitution, following bone marrow or stem cell transplantation, requires a microenvironment niche capable of supporting both immature progenitors and stem cells with the capacity to differentiate and expand. Osteoblasts comprise one important component of this niche. We determined that treatment of human primary osteoblasts (HOB) with melphalan or VP-16 resulted in increased phospho-Smad2, consistent with increased TGF-β1 activity. This increase was coincident with reduced HOB capacity to support immature B lineage cell chemotaxis and adherence. The supportive deficit was not limited to committed progenitor cells, as human embryonic stem cells (hESC) or human CD34+ bone marrow cells co-cultured with HOB pre-exposed to melphalan, VP-16 or rTGF-β1 had profiles distinct from the same populations co-cultured with untreated HOB. Functional support deficits were downstream of changes in HOB gene expression profiles following chemotherapy exposure. Melphalan and VP-16 induced damage of HOB suggests vulnerability of this critical niche to therapeutic agents frequently utilized in pre-transplant regimens and suggests that dose escalated chemotherapy may contribute to post-transplantation hematopoietic deficits by damaging structural components of this supportive niche